Tag: BD glucan

Mehraj, Vikram, et al. “Circulating (1→3)-β-D-glucan Is Associated With Immune Activation During Human Immunodeficiency Virus Infection.” Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 70, no. 2, 2020, pp. 232-241.

This is a cross-sectional and longitudinal assessment of BD glucan levels in 146 patients living with HIV. Within this cohort, 53 had been diagnosed within 6 months, 22 had chronic HIV but no ART, and 71 had chronic HIV and were on ART. These were then compared to 42 uninfected controls. The study design is

Continue reading
No comments

Chang, Euijin, et al. “Limited Positive Predictive Value of β-d-Glucan in Hematologic Patients Receiving Antimold Prophylaxis.” Open Forum Infectious Diseases, vol. 7, no. 3, 2020, pp. ofaa048.

Retrospective study from South Korea evaluating the predictive value of BD glucan in the age of mold active triazole prophylaxis. They recruited patients that underwent induction chemotherapy, SCT, or GVHD treatment that had BD glucans throughout their stay while on posa or micafungin prophylaxis. They defined a positive BD glucan as 2 or more BDG

Continue reading